Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Date:9/16/2008

SAN CARLOS, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2008 Global Life Sciences Conference in New York at the Grand Hyatt New York Hotel on Tuesday, September 23, 2008 at 10:30 a.m. ET.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 25, 2008.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled eight approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

CONTACT:

Jennifer Ruddock

Nektar Therapeutics

1-650-283-6253

jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...Newswire/ - Aegera Therapeutics Inc. announced tod... Phase 2B study of AEG35156, a targeted antisense ...oncology indications. ,, The study, entitled "A...ked Inhibitor of Apoptosis (XIAP) Antisense AEG351...and Idarubicin in AML Following Failure of a Singl...
(Date:11/18/2009)... Marrone Bio Innovations (MBI), a ...lization of effective and environmentally responsi...s been named an IC20 company by the Investors, Cir...l angel investing group. ,, Companies named to ... results for all stakeholders, including investors...
(Date:11/18/2009)...v. 18 Sangamo BioScience... from the University of Pennsylvania investigator ...inger nuclease (ZFN) based product, SB-728-T, for ...sed on the internet. ,, Data were presented in ... School of Medicine from a single subject treated ...
(Date:11/18/2009)...18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (N... development company that identifies and advances ...oducts at various stages of development, announced...were presented today in a poster at the 2009 AACR-...s conference in Boston, Massachusetts. The reporte...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
...8 Bio-Pharma executives are,increasingly finding ...d by,Best Practices, LLC and in particular in use ... Best Practice Database (, http://www.BestPractice...ase,may be accessed and downloaded individually, m... find outstanding value in membership to the datab...
...harmaceuticals,(Nasdaq: SGXP ) today announced it...nded June 30, 2008. For the three months ended Jun...llion and a net loss of $7.2 million. For,the six ...llion and the net,loss was $3.5 million. The reven...of revenue earned in the first quarter attributabl...
...if., Aug. 7 Anesiva,Inc. (Nasdaq: ANSV ) today r...the second quarter and six months ended June 30, 2...nt advance for Anesiva as we,introduced Zingo(TM) ...el,L. Kranda, president and chief executive office...ase 3 trials of Adlea(TM) for the management of ac...
Other Biology Technology:Best Practice Database Supports Bio-Pharma Product Launch 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 3SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 4SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 5SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 6SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 7SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 8SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 9Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8
(Date:11/20/2009)...dust: Toxins in coal-tar-based sealcoats in parkin...st, according to a USGS study. PAHs or polycycli... in oil, coal and tar deposits, and can have toxic... found in house dust; however, the specific source...ers found that dust from indoor areas near parking...
(Date:11/20/2009)...uctive pulmonary disease (COPD), a respiratory dis...sema, is the fourth leading cause of death worldwi...esearchers have yet to find any real treatment or ...at The University of Western Ontario in London, Ca...new insight into the disease. , Parraga is a...
(Date:11/19/2009)...-cutter ants, which cultivate fungus for food, hav... to add to the list: the ant farmers, like their h...ria to make their gardens grow. The finding, repor...documents a previously unknown symbiosis between a...f-cutter ants have come to dominate the American t...
Breaking Biology News(10 mins):From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Gaining a better picture of lung disease 2Like humans, ants use bacteria to make their gardens grow 2ISSA Announces New Specialist in Fitness Nutrition Certification 52175 1ISSA Announces New Specialist in Fitness Nutrition Certification 52175 2Pharmaxis Investor Conference Call 13112 1New report 3A Individual health insurance market failing consumers 52173 1New report 3A Individual health insurance market failing consumers 52173 2New report 3A Individual health insurance market failing consumers 52173 3New report 3A Individual health insurance market failing consumers 52173 4
...ome,Research that they have successfully cloned an...nce: a 554-kilobase-pair genomic,segment near the ...e,contains eight putatively active genes that coul...es and gonadal tumor development. , This,pericentr...he,"finished" sequence of the human genome reporte...
...that was originally believed to be involved in tub...sing enzyme" from the biosynthetic pathway for an ... research appears as the "Paper of the Week" in th...stry, an American Society for Biochemistry and Mol...sis, the causative agent of tuberculosis, is respo...
...r,has been announced by Agilent Technologies. The ...bles the rapid advance of microarray-based,compara...eport,published in the December 24, 2004 issue of ... (PNAS) in collaboration with the National,Human G...specialised,microarray platform that uses total ge...
Other Biology News:Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Scientists find missing enzyme for tuberculosis iron scavenging pathway 2Breakthrough Microarray-based Technology for the Study of Cancer 2
Gey's Balanced Salt Solution (GBSS) from Sigma-Aldrich
...cations to the original formulas in efforts to pro...y an important role in tissue,culture. A salt solu...tic balance in the medium and to provide the cells...luable today as when it was first developed a cent...
Ellman's Reagent from Cayman Chemical
Synergy HT Multi-Detection Microplate Reader from BioTek Instruments
Biology Products: